inbrx-106
·Code: INBRX-106
inbrx-106: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Inhibrx Biosciences, Inc. (INBX) | Phase 2/Phase 3 |
Clinical Trials (1)
A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (HexAgon-HN)
Frequently asked questions
Who is developing inbrx-106?
inbrx-106 is being developed by Inhibrx Biosciences, Inc..
How many clinical trials involve inbrx-106?
BioSniper tracks 1 clinical trial involving inbrx-106.
Get deeper analysis on inbrx-106
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis